Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514)
European Journal of Cancer · 2023
DOI: 10.1016/j.ejca.2023.04.025 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Carole Soussain und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Institut Curie, Site Saint-Cloud, Saint-Cloud, France. Electronic address: carole.soussain@curie.fr. Hauptthemen laut MEDLINE: Retinal Neoplasms, Lymphoma, Central Nervous System Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hematology, Institut Curie, Site Saint-Cloud, Saint-Cloud, France. Electronic address: carole.soussain@curie.fr.
- Ophthalmology, Institut Curie, Site Paris, Université Paris V Descartes et PSL (Paris Science et Lettre), Paris, France.
- Hematology, APHP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
- Hematology, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon 1, Pierre-Bénite, France.
- APHP, Sorbonne Université, IHU, ICM, Neurology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Zitieren
APA
Soussain, C., Malaise, D., Choquet, S., Ghesquières, H., & Houillier, C. (2023). Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.04.025
Vancouver
Soussain C, Malaise D, Choquet S, Ghesquières H, Houillier C. Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514). European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.04.025
BibTeX
@article{Soussain2023,
author = {Soussain, Carole and Malaise, Denis and Choquet, Sylvain and Ghesquières, Hervé and Houillier, Caroline},
title = {Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514)},
journal = {European Journal of Cancer},
year = {2023},
doi = {10.1016/j.ejca.2023.04.025}
}
EUVIMED